Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, Adma Biologics (ADMA) closed at $15.60, marking a +2.77% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.23%. Elsewhere, the Dow gained 0.72%, while the tech-heavy Nasdaq added 1.86%. The stock of infectious disease drug developer has fallen by 2.75% in the past month, lagging the Medical sector's gain of 4.41% and the S&P 500's gain of 2.45%.The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $130.1 million, showing a 8.56% escalation compared to the year-ago quarter. ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $506.7 million. These results would represent year-over-year changes of +16.33% and +18.82%, respectively. Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics currently has a Zacks Rank of #3 (Hold). In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 26.63. For comparison, its industry has an average Forward P/E of 20.3, which means Adma Biologics is trading at a premium to the group. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 92, this industry ranks in the top 38% of all industries, numbering over 250. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks